LXRX Q2 2024 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+419.6% YoY

Gross Profit

$1M89.9% margin

Operating Income

-$55M-3360.9% margin

Net Income

-$53M-3244.0% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+45.8%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$373M

Total Liabilities

$133M

Stockholders' Equity

$240M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$317,000	+419.6%
Gross Profit	$1M	$309,000	+379.3%
Operating Income	-$55M	-$44M	-25.1%
Net Income	-$53M	-$45M	-19.0%